Cargando…
Open‐label long‐term treatment of add‐on triheptanoin in adults with drug‐resistant epilepsy
OBJECTIVE: To investigate feasibility, safety, and tolerability of long‐term (48 weeks) add‐on treatment with triheptanoin (UX007), the triglyceride of heptanoate, in adults with drug‐resistant epilepsy. METHODS: This extension study was offered to adult participants with drug‐resistant epilepsy who...
Autores principales: | Borges, Karin, Kaul, Neha, Germaine, Jack, Carrasco‐Pozo, Catalina, Kwan, Patrick, O’Brien, Terence J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278596/ https://www.ncbi.nlm.nih.gov/pubmed/32524048 http://dx.doi.org/10.1002/epi4.12391 |
Ejemplares similares
-
Randomized trial of add‐on triheptanoin vs medium chain triglycerides in adults with refractory epilepsy
por: Borges, Karin, et al.
Publicado: (2019) -
Long‐term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11‐year, open‐label, follow‐up trial
por: O’Brien, Terence J., et al.
Publicado: (2020) -
Cathodal transcranial direct‐current stimulation for treatment of drug‐resistant temporal lobe epilepsy: A pilot randomized controlled trial
por: Zoghi, Maryam, et al.
Publicado: (2016) -
Triheptanoin: First Approval
por: Shirley, Matt
Publicado: (2020) -
Correction to: Triheptanoin: First Approval
por: Shirley, Matt
Publicado: (2020)